Generic filters
Filter by content type
Taxonomy terms

TBPH – Theravance Biopharma Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 10.57

Low: 8

High: 14

Total Analysts: 7

Company Profile

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. The Company develops transformational medicines to improve the lives of patients suffering from respiratory illnesses. The Company’s research is engaged in the areas of inflammation and immunology. Its Nezulcitinib (TD-0903) product is a lung-selective pan Janus-associated kinase inhibitor designed for inhaled delivery, is under development for treatment of acute lung injury associated with coronavirus disease 2019. The Company is also developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Velusetrag (TD-5108), Selective 5-HT4 Agonist (TD-8954).

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan